Skip to main content
. 2022 Oct 17;127(12):2154–2165. doi: 10.1038/s41416-022-01969-2

Table 1.

Patient characteristics.

Variables N = 81
Age, years
 Average (range) 62.5 (35–84)
Gender, n (%)
 Male 54 (66.7)
 Female 27 (33.3)
Smoking history, n (%)
 Current 22 (27.2)
 Former 7 (8.6)
 Never 52 (64.2)
Lesion size, n (%)
 ≤30 mm 22 (27.2)
 >30 mm 59 (72.8)
Biopsy location showed by EBUS, n (%)
 Central 64 (79.0)
 Peripheral 17 (21.0)
Atypical cells in BWF_Pre, n (%)
 Yes 39 (48.1)
 No 42 (51.9)
Histologic type, n (%)
 Adenocarcinoma 54 (66.7)
 Squamous cell carcinoma 8 (9.9)
 Adenosquamous cell carcinoma 1 (1.2)
 Large cell lung endocrine carcinoma 3 (3.7)
 Small cell lung carcinoma 1 (1.2)
 Non-malignancy 14 (17.3)
Clinical stage, n (%)
 I 8 (9.9)
 II 11 (13.6)
 III 15 (18.5)
 IV 33 (40.7)
Not applicable 14 (17.3)
TKI treatment, n (%)
 Yes 5 (6.2)
 No 76 (93.8)

EBUS endobronchial ultrasound, BWF_Pre bronchial washing fluid precipitant, TKI tyrosine kinase inhibitor.